Diagnosis of Pancreatic Cancer by Purine Metabolite (Hypoxanthine, Xanthine) in Urine
This study aim to develope a diagnostic method of pancreatic cancer by using a reagent for analyzing purine metabolite (Hypoxanthine, Xanthine) in urine.
It is safe and cost effective compare to radiologic or blood test. It can be used for initial screening test for healty population.
- EligibilityCriteria: pancreatic cancer group  Inclusion Criteria:  Pancreatic ductal adenocarcinoma that is pathologically confirmed or shows characteristic radiologic features Patients with resectable pancreatic cancer at the time of surgery (Including borderline resectable pancreatic cancer at the time of diagnosis or Locally advanced pancreatic cancer after chemotherapy or radiation therapy) Patients without invasion of adjacent organs other than the left adrenal gland and mesocolon Patients with informed consent  Exclusion Criteria:  History of other malignancy (Inclusive if there is no evidence of recurrence after 5 years of treatment) Patient with Inflammatory disease(e.g. severe pancreatitis, cholangitis) Patients with underlying diseases at high risk of general anesthesia Other subject whom the investigator deems inappropriate control group Inclusion Criteria included healthy individuals as well as patients with benign diseases.  Exclusion criteria for the control group included a previous cancer diagnosis within the past five years, active inflammatory diseases, borderline malignant pancreatic tumors, or a postoperative pathological finding of malignancy. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Pancreatic cancer group: comprised patients who were scheduled for curative surgery for pancreatic cancer  Control group: The control group included healthy individuals as well as patients with benign diseases - SamplingMethod: Non-Probability Sample